StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$41.31−0.19 (-0.46%)

Close on Oct 19, 2026Market cap $48.13BP/E 68.9Yield –

Teva Pharmaceutical Industries GAAP Operating Income / (Loss) Margin by Quarter

GAAP Operating Income / (Loss) Margin (%) (%)

Teva Pharmaceutical Industries GAAP Operating Income / (Loss) Margin: 16.2% in Q3 2026, down 3.5 pts from a year earlier.

Latest, Q3 2026
16.2%
Period ended Sep 30, 2026
Change on a year earlier
-3.5 pts
19.7% in Q3 2025
History
17 quarters
Since Q4 2021
Sources
13
Documents cited below

Where the Q3 2026 figure comes from

“|| Operating margin | 16.2 % | 19.7 % | 9.1 % | 14.8 %”

Source: Form 8-K Earnings Release (0001171843-26-007054) ↗

Reported in SEC Form 10-K / Form 10-Q / Form 8-K Earnings Releases.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedGAAP Operating Income / (Loss) Margin (%) (%)Year on yearSource
Q3 2026Sep 30, 202616.2%-3.5 ptsForm 8-K Earnings Release (0001171843-26-007054) ↗
Q2 2026Jun 30, 2026-5.6%-16.5 ptsForm 8-K Earnings Release (0001171843-26-004974) ↗
Q1 2026Mar 31, 202616.4%+3.1 ptsForm 8-K Earnings Release (0001171843-26-002796) ↗
Q4 2025Dec 31, 20256.4%+5.7 ptsForm 8-K Earnings Release (0001171843-26-000462) ↗
Q3 2025Sep 30, 202519.7%+20.9 ptsForm 8-K Earnings Release (0001171843-25-007000) ↗
Q2 2025Jun 30, 202510.9%+11.0 ptsForm 8-K Earnings Release (0001171843-25-004808) ↗
Q1 2025Mar 31, 202513.3%+19.0 ptsForm 8-K Earnings Release (0001171843-25-002849) ↗
Q4 2024Dec 31, 20240.7%–Form 8-K Earnings Release (0001171843-25-000493) ↗
Q3 2024Sep 30, 2024-1.2%-10.4 ptsForm 8-K Earnings Release (0001171843-24-006034) ↗
Q2 2024Jun 30, 2024-0.1%+16.8 ptsForm 8-K Earnings Release (0001171843-24-004270) ↗
Q1 2024Mar 31, 2024-5.7%-5.8 ptsForm 8-K Earnings Release (0001171843-25-002849) ↗
Q3 2023Sep 30, 20239.2%-2.4 ptsForm 8-K Earnings Release (0001157523-23-001677) ↗
Q2 2023Jun 30, 2023-16.9%–Form 8-K Earnings Release (0001171843-24-004270) ↗
Q1 2023Mar 31, 20230.1%–Form 8-K Earnings Release (0001157523-23-000797) ↗
Q4 2022Dec 31, 2022-22.0%-23.9 ptsForm 8-K Earnings Release (0001157523-23-000205) ↗
Q3 2022Sep 30, 202211.6%–Form 8-K Earnings Release (0001157523-23-001677) ↗

Cite this data

StockData. (2026). Teva Pharmaceutical Industries GAAP Operating Income / (Loss) Margin (%), quarterly Q4 2021–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/ng-gaap-op-margin

See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?